Leela Prasad Kowtharapu1,2, Naresh Kumar Katari2,3, Christian A Sandoval1, Vijay Kumar Rekulapally4, Sreekantha Babu Jonnalagadda3. 1. Analytical Development Department, Shenzhen DEC Pharmaceutical Co., Ltd, Shenzhen 518057, China. 2. Department of Chemistry, GITAM School of Science, Gandhi Institute of Technology and Management, Hyderabad, Telangana 502329, India. 3. School of Chemistry & Physics, College of Agriculture, Engineering & Science, Westville Campus, University of KwaZulu-Natal, P Bag X 54001, Durban-4000, South Africa. 4. Analytical Research and Development, Hikma Pharmaceuticals USA Inc, Columbus, Ohio 43228, United States.
Abstract
We report an efficient HPLC method for simultaneous qualitative and quantitative analysis of lincosamide antibiotic injectable formulations containing Clindamycin phosphate (CMN), benzyl alcohol (BA), and ethylenediaminetetraacetic acid (EDTA) as major ingredients. The three components were separated by Phenomenex prodigy C8 (250 mm × 4.6 mm, 5 μm) HPLC column, flow rate 1.1 mL/min, injection volume 30 μL, and column temperature 35 °C, using 0.05 M sodium acetate buffer (pH 4.5) with acetonitrile (ACN) in the ratio of 80:20 (v/v). The detection wavelength was set as 240 nm. The method was validated as per International Conference on Harmonization (ICH) guidelines and was confirmed to be specific, precise, accurate, and linear. Method robustness was executed by utilizing quality in the design of the experiment. Accuracy results were found to be 99.3-100.5% for CMN, 99.3-100.8% for BA, and 99.1-100.3% for EDTA. Precision results were obtained as % relative standard deviation (RSD): 0.6% for CMN, 0.4% for BA, and 0.4% for EDTA. Correlation coefficient (r 2) values were obtained as >0.999 for the three components. Analytical solutions are stable for 48 h at benchtop and refrigerator conditions. The greenness of the analytical method was evaluated by the Green Analytical Procedure Index (GAPI), National Environmental Method Index (NEMI), analytical eco-scale, and Analytical Greenness (AGREE) tools to confirm that the method is eco-friendly.
We report an efficient HPLC method for simultaneous qualitative and quantitative analysis of lincosamide antibiotic injectable formulations containing Clindamycin phosphate (CMN), benzyl alcohol (BA), and ethylenediaminetetraacetic acid (EDTA) as major ingredients. The three components were separated by Phenomenex prodigy C8 (250 mm × 4.6 mm, 5 μm) HPLC column, flow rate 1.1 mL/min, injection volume 30 μL, and column temperature 35 °C, using 0.05 M sodium acetate buffer (pH 4.5) with acetonitrile (ACN) in the ratio of 80:20 (v/v). The detection wavelength was set as 240 nm. The method was validated as per International Conference on Harmonization (ICH) guidelines and was confirmed to be specific, precise, accurate, and linear. Method robustness was executed by utilizing quality in the design of the experiment. Accuracy results were found to be 99.3-100.5% for CMN, 99.3-100.8% for BA, and 99.1-100.3% for EDTA. Precision results were obtained as % relative standard deviation (RSD): 0.6% for CMN, 0.4% for BA, and 0.4% for EDTA. Correlation coefficient (r 2) values were obtained as >0.999 for the three components. Analytical solutions are stable for 48 h at benchtop and refrigerator conditions. The greenness of the analytical method was evaluated by the Green Analytical Procedure Index (GAPI), National Environmental Method Index (NEMI), analytical eco-scale, and Analytical Greenness (AGREE) tools to confirm that the method is eco-friendly.
Clindamycin phosphate
(CMN) is an injectable lincosamide antibiotic
to prevent bacterial infections. The CMN injectable formulation contains
two other primary ingredients, benzyl alcohol (BA) and ethylenediaminetetraacetic
acid (EDTA). It also contains hydrochloric acid and sodium hydroxide
as minor components for pH adjustment purposes. Specifically, CMN
is a water-soluble ester of lincomycin, formed by the 7(S)-chloro-substitution of the parent antibiotic 7(R)-hydroxyl, and CMN is available as a phosphate salt. The molecular
formula and molecular weight are C18H34ClN2O8PS and 505.0, respectively. The compound BA consists
of benzene with a hydroxymethyl substitution. It is a metabolite,
a solvent, a fragrance, an antioxidant, and an insect repellent.EDTA is an aminopoly(carboxylic acid) with the formula [CH2N(CH2CO2H)2]2.
As a hexadentate chelating agent, this white, water-soluble solid
is typically used to bind iron and calcium ions. EDTA is available
in several salt forms, including sodium calcium edetate, disodium
EDTA, and tetrasodium EDTA. EDTA is used as a chelating agent in this
formulation. The chemical structures of CMN (active), BA (preservative),
and EDTA (antioxidant) are shown in Figure .
Figure 1
Structures of clindamycin phosphate (A), EDTA
(B), and benzyl alcohol
(C).
Structures of clindamycin phosphate (A), EDTA
(B), and benzyl alcohol
(C).As per the current Committee for Proprietary Medicinal
Products
(CPMP), the Committee for Veterinary Medicinal Products (CVMP) regulatory
guidance, document numbers CPMP/CVMP/QWP/115/95,[1] CPMP/QWP/419/03,[2] USP general
chapter ⟨341⟩,[3] and ICH topic
Q6 A,[4] antioxidants and antimicrobial preservative
levels in the formulation should be qualitative and quantitatively
monitored periodically during the shelf life of the finished product.
The present formulation had both preservatives and antioxidants. In
the stability study of the finished product, the content levels of
BA and EDTA are monitored using two different analytical methods.
There is no method available for combined determination with the presence
of CMN. Many analytical techniques are available for individual analysis
of BA.[5−8] EDTA is a UV inactive component, and few authors made the analyte
UV active by a derivatization process and determined by using different
techniques.[9−16] Several kinds of literature are available for the CMN content determination
in different formulations.[17−21] Two reports are available to determine EDTA and BA by HPLC and MS
analyses.[22,23]Assay determination of CMN, BA, and
EDTA by three diverse methods
is time-consuming, expensive, and not viable in regular pharmaceutical
quality control laboratories. The current research targeted the single
analytical method for all three analytes in a simple RP-HPLC isocratic
way; simultaneously, the technique should be eco-friendly and cost-effective.
The added derivatizing agent to make EDTA UV sensitive should not
interfere with the BA and CMN peak shapes and recoveries.Methods
and techniques of analysis play a significant role in QbD.
DoE (Design of Experiment) is commonly used to find ranges for operating
parameters of the equipment, understand sample preparation variations,
and evaluate method robustness. Design Expert software ver. 13 is
used for design space trails with identified critical quality attributes.[24] The QbD tool is used to study the method’s
robustness.Green Analytical Procedure Index (GAPI), National
Environmental
Method Index (NEMI), and Analytical Eco-scales are employed for green
chemistry evaluations. GAPI is a pictogram design, and it is a valuable
tool to evaluate the method’s greenness in all aspects, including
sample collection, sample preparation, technique, and determination.
NEMI is also a pictogram that assesses the process by corrosion, waste,
hazardous, and PBT (persistent, bioaccumulative, and toxic). Analytical
eco-scale is another green chemistry metric that evaluates the method
by calculating the penalty points and expresses the method’s
eco-friendliness. These three green metrics were utilized to confirm
the method’s greenness.[29−34] The modern tool Analytical Greenness (AGREE) is also used to assess
greenness. The approach was devised by the Gdańsk University
of Technology, Poland, and expresses the greenness of the procedure
based on 12 green chemistry principles.[35]
Results and Discussion
Method Development
Generic injectable
formulations do not require clinical studies to be submitted to the
regulatory agency. The contents of the formula with the reference
listed drugs have to be attested as being qualitatively and quantitatively
identical for the dosage form submissions. The current formulation
contains two major excipients, BA and EDTA. For regulatory compliance,
it is essential to prove that these components are the same as the
reference sample. Moreover, as per the regulatory body requirements,
the levels of antioxidants and antimicrobial preservatives should
be monitored in the stability study of the formulation. In small-scale
laboratories, determining these contents using different methods and
high-end techniques is unreliable. HPLC is the most widely used simple
technique in the pharmaceutical industry. Current research targeted
a single and straightforward isocratic RP-HPLC method to determine
these excipients and the active drug. CMN is the therapeutically active
ingredient, and BA is used as a preservative in the current formulation.
BA protects the formulation from microbial growth throughout the lifetime
of injection. Both are UV active, so no special treatment is required
to quantify in sample preparation.EDTA stabilizes the formulation
by chelating free ions and metals present in the formulation, which
may trigger the degradation reaction of the active component. EDTA
is commonly used as a chelating agent in biochemistry, cellular biology,
and molecular biology to bind divalent metal ions (such as calcium
and magnesium). Metals are bound to EDTA through amine and carboxylate
groups. Mn (II), Cu (II), Fe (III), Pb (II), and Co (III) form strong
EDTA complexes. HPLC analysis of EDTA is complicated due to its UV
inactivity and strong metal ion binding tendency. The method’s
sensitivity is increased by using copper acetate as a derivatizing
agent. Cu (II) ions react with EDTA to form a UV-active complex. Copper
II acetate was chosen based on its nontoxic nature, eco-friendliness,
cost-effectiveness, and compatibility with the drug. The copper acetate
reaction with EDTA is shown in Scheme .
Scheme 1
EDTA UV-Active Complex Formation by Reaction with
Copper Acetate
Based on the literature review, we initiated
chromatography optimization
trials with C18 and C8 stationary phases with potassium phosphate,
sodium phosphate, and orthophosphoric acid buffers with the ACN combination
at pH 4.5. Based on the available literature and pKa values of EDTA and CMN, mobile-phase buffer pH was selected
as pH 4.5. BA and CMN were eluted in all the conditions. The derivatized
and UV-activated EDTA complex was not eluted. Compared with C18 stationary
phase columns, the C8 stationary phase column results were more satisfactory
due to its less hydrophobic nature, and peaks eluted more quickly
than the C18 stationary phase. Hence, for further evaluation the C8
column was chosen. Different mobile phases were prepared with basic
ion-pairing reagents, triethylamine, tetrabutylammonium hydroxide,
and sodium 1-heptanesulfonate to increase the ionization capacity
and elute EDTA. Tetrabutylammonium hydroxide 10% in water showed promising
results, and it was considered for further evaluation. Mobile phase
A changed to pH 4.5 sodium acetate 0.05 M buffer, and 15 mL of tetrabutylammonium
hydroxide 10% in water was added. ACN was used as a mobile phase B.
Using the Phenomenex prodigy C8 (250 mm × 4.6 mm, 5 μm)
column and CMN and BA elution with a 1.0 mL/min flow rate, chromatography
was conducted with acetonitrile buffer in a 90:10 (v/v) ratio. The
EDTA peak eluted at about 18 min. CMN and BA could not be eluted under
these conditions. Different organic ratios examined did not reduce
the EDTA retention time or elute CMN and BA. The results concluded
that the ion-pairing reagent concentration was affecting the retention
time of the EDTA. The minimum amount of 8 mL was selected per 1 L
of buffer, the organic ratio changed to 20%, and BA and CMN samples
were injected individually. CMN, BA, and EDTA in separate samples
eluted under the same chromatographic conditions. Lambda max 240 nm
was selected based on the EDTA spectrum due to the low amount of EDTA
present in the formulation. Using single chromatographic conditions
and preparing the different samples for different analytes was not
the objective. The CMN and BA samples were prepared with the derivatizing
agent (Copper II acetate) and injected to overcome the problem. BA
and CMN peaks were eluted, but CMN eluted with a broader peak, and
peak fronting was observed. The diluent’s concentration of
derivatizing agent was varied to improve the CMN peak shape. The diluent
was prepared with the derivatizing agent at different concentations
(5, 10, and 20 mg/mL). The standard and sample solutions are injected
into HPLC. All the peaks were eluted with good peak shape with 10
mg/mL of derivatizing agent and met the system suitability requirements.
Chromatographic conditions were optimized with a Phenomenex C8 (250
mm × 4.6 mm, 5 μm) HPLC column with a 1.1 mL/min flow rate.
The mobile phase ratio fixed buffer:acetonitrile at 80:20 (v/v), lambda
max was attained at 240 nm, and the column compartment temperature
was set at 35 °C. The total run time of 20 min was finalized
based on the robustness and specificity results. The final optimized
chromatogram is shown in Figure .
Figure 2
Final chromatogram with optimized conditions, flow rate
1.1 mL/min,
column temperature 35 °C, injection volume 30 μL, and wavelength
240 nm with Phenomenex prodigy C8 (250 mm × 4.6 mm, 5 μm)
column.
Final chromatogram with optimized conditions, flow rate
1.1 mL/min,
column temperature 35 °C, injection volume 30 μL, and wavelength
240 nm with Phenomenex prodigy C8 (250 mm × 4.6 mm, 5 μm)
column.To check the effect of the derivatizing agent on
the CMN and BA,
samples were prepared with and without Copper II acetate, and the
analyte assay values were calculated. Table summarizes the results.
Table 1
Derivatizing Agent Affect: % Assay
of Clindamycin, EDTA, and Benzyl Alcohol with and without Derivatizing
Agent in 3 Batches
Batch No
With agent
Without agent
Clindamycin (CMN)
1
99.5%
99.1%
2
98.7%
99.5%
3
99.6%
99.1%
Benzyl alcohol
(BA)
1
100.5%
99.6%
2
99.8%
98.7%
3
98.6%
98.3%
Ethylenediaminetetraacetic
acid (EDTA)
1
98.9%
Not detected
2
100.1%
Not detected
3
99.5%
Not detected
The results express the impact of the derivatizing
agent on EDTA
clearly. With the derivatizing agent, the EDTA peak eluted with recovery
>98.9%. Without the agent, the EDTA peak was not detected. No impact
if the derivatizing agent on CMN and BA was observed. The % difference
between with and without derivatizing agent CMN and BA was 0.1% and
0.3%, respectively.
Conclusions
A green reverse-phase liquid
chromatographic method is developed
for the quantitative analysis of active ingredient (Clindamycin phosphate),
preservative (benzyl alcohol), and chelating agent (ethylenediaminetetraacetic
acid) in Lincosamide injectable antibiotic formulations. This RP-HPLC
method was validated per the ICH and proved specific, precise, accurate,
robust, and stability-indicating. The developed and validated process
was simple, sensitive, and economical. A single determination of all
three components is a significant asset of this method. Therefore,
the proposed method is reliable, suitable for routine analysis, and
an excellent approach to obtaining reliable results. This protocol
can be used even for the individual determination of CMN, EDTA, and
benzyl alcohol. The proposed method is environmentally friendly.
Materials and Methods
Chemicals and Reagents
Grade A glassware
was used in the complete development and validation. In the mobile
phase preparation, buffer salt sodium acetate, acetonitrile (HPLC
grade), and pH adjustment chemical glacial acetic acid (AR grade)
were procured from Merck (Merck Chemicals (Shanghai) Co., Ltd.). The
ion pairing reagent tetrabutylammonium hydroxide 10% in water (HPLC
grade) was procured from JT Baker. The EDTA UV activation derivatizing
agent, copper II acetate (AR grade), was obtained from Sino Pharm
Chemical Reagents, China. EDTA and BA were obtained from Merck (Merck
Chemicals (Shanghai) Co., Ltd.), and CMN was purchased from Hubei
Yitai Pharmaceutical Co., Ltd., China. For stress studies, hydrogen
peroxide, sodium hydroxide, and hydrochloric acid (AR grade) were
procured from Sino Pharm Chemical Reagents, China. Milli-Q water was
used throughout the studies. Formulation and placebo samples were
prepared in-house.
Equipment, Software, and Column
The
chromatography method was developed with a Prodigy C8 (250 mm ×
4.6 mm, 5 μm) column from Phenomenex. Agilent Technologies,
Model 1100 series with UV and DAD detectors, was used for liquid chromatography.
We used Open lab CDS software to run the HPLC. Shimadzu AP225WD semi-microbalance
was used for weighing chemicals. Buffer pH 4.5 was prepared by using
the Mettler pH meter model no FE-28. The buffer was filtered with
a vacuum pump from HA diaphragm model no. HPD-25B. Olavo water bath
(Model DHG-9250A) and vacuum oven (HS-56) were used for the forced
degradation study with model numbers. Photo stress was performed on
the Yesi drug photostability chamber model no. SHH-100GD-2. Design
Expert software ver. 13 was used for a robustness study by DoE (design
of experiments).
Analytical Solution Preparation
The
mobile phase was prepared by mixing the buffer (8 mL of tetrabutylammonium
hydroxide 10% in water diluted with 0.05 M pH 4.5 sodium acetate buffer,
pH adjusted with acetic acid) and ACN in the ratio of 80:20 (v/v).
Diluent for the sample and standard preparation was prepared by mixing
the buffer, ACN, and copper II acetate solution (10 mg/mL) in the
ratio of 78:20:2 (v/v/v). Standard solution concentrations of EDTA
5 μg/mL, BA 95 μg/mL, and CMN 1500 μg/mL were prepared
by transferring 10.0 mg of EDTA and 19.0 mg of BA in a 20 mL diluent,
then equivalent to 15.0 mg of CMN, and 1 mL of the previous solution
diluted to 10 mL. Test sample solutions were prepared by diluting
1.0 mL of the injection sample solution into 50 mL with diluent and
injecting all samples into the HPLC system.
Chromatography Conditions
A single
and straightforward isocratic method developed with Phenomenex prodigy
C8 (250 mm × 4.6 mm, 5 μm) column was used. 0.05 M pH 4.5
buffer mixed with acetonitrile in the ratio of 80:20 (v/v) was used
as the mobile phase and was filtered through a 0.45 μm membrane
filter. Flow rate was 1.1 mL/min, injection volume was 30 μL,
column temperature was 35 °C, and the detection was done at 240
nm. The total isocratic run was 20 min.
Analytical Method Validation
ICH
guidelines Q2 (R1)[26] and USP general chapter
⟨1225⟩[27] were followed in
the validation of the current method. All the validation results were
tabulated in Table .
Table 2
Analytical Method Validation Data
Parameter name
EDTA
BA
CMN
System suitability
Tailing factor (<2.0)
1.3
1.2
0.9
Plate count
(>2000)
50906
100154
75963
RSD% (n = 6 < 2.0)
0.3
0.4
0.8
Specificity
Diluent/Mobile phase Interference (Should be absent)
No interference
No interference
No interference
Placebo interference (Should be absent)
No Interference
No Interference
No Interference
Peak purity (Should be passed)
Passed
Passed
Passed
Linearity
Range (μg/mL)
1.2–7.5
23.6–141.8
375–2250
Slope
139668
197415
239230
Intercept
102.05
349.85
756.46
Correlation
coefficient >0.999
0.9999
0.9999
0.9994
LOQ (μg/mL)
0.04
0.03
0.02
Accuracy (n = 6 avg
Percentage)
LOQ level ± SD
100.5 ± 0.3
100.8 ± 0.6
100.3 ± 0.9
80% mean ±
SD
100.1 ± 0.5
99.6 ± 0.2
99.1 ± 0.6
100% mean ± SD
99.3 ± 1.1
99.9 ± 0.9
99.5 ± 0.4
120% mean ± SD
100.3 ± 1.1
99.3 ± 0.1
99.6 ± 1.5
Precision (Interday, n = 6 RSD% < 2.0)
0.5
0.4
0.6
Intermediate Precision (Intraday, n = 6 RSD% < 2.0)
0.8
0.8
0.8
Ruggedness (n = 12 RSD% < 2.0)
0.6
0.6
0.7
Solution stability B.T (0 and 24 h % difference <2.0)
0.3
0.5
0.8
Solution stability 2–8 °C
(0 and 24 h % difference <2.0)
0.6
0.4
1.3
Solution stability B.T (0 and 48 h % difference <2.0)
1.3
0.5
1.6
Solution stability 2–8 °C
(0 and 48 h % difference <2.0)
1.6
1.1
1.4
Specificity
Specificity is the
capability to quantify analyte characteristics in the presence of
other components expected to subsist. The specificity of the method
was verified by injecting the mobile phase, placebo, individual impurities
of CMN, and standard and sample solutions in a PDA system. No optical
interference was noticed with mobile phase, placebo, and impurity
solutions. Peak purity was passed for three analytes, which expresses
the specificity of the method.
Forced Degradation Study
The idea
behind forced degradation is that a substance or product was subjected
to different stress conditions before its degradation. In the industry
context, a stability-indicating method is an analytical procedure
that eliminates the interference of process impurities, excipients,
and degradation products with the desired analyte. The current method’s
stability-indicating nature was proven by conducting acid, base, peroxide,
thermal, and light degradation studies.[25] Degradation results expressed that the formulation product was sensitive
to all the conditions. The major degradants were CMN EP impurity E
and CMN EP impurity F. These peaks clearly separated from the three
analytes. All the requirements for peak purity were passed, and no
interference was observed with degradant peaks. No interference was
observed at the retention of EDTA, CMN, and BA. Forced degradation
data were summarized in Table .
Table 3
Forced Degradation Data of Clindamycin
Condition
% Degradation sample
Assay (% w/w) in degradation sample
Purity index
Single point
threshold
Peak purity
Control sample (unstressed)
1.15
98.8
1.000
0.999
Passed
Acid degradation 1 M; HCl 120 min
at @ 80 °C
11.50
86.6
1.000
0.998
Passed
Base degradation 1 M; NaOH 1 min
@ 80 °C
16.50
82.5
1.000
0.996
Passed
Peroxide Stress 0.5% H2O2
11.30
85.5
1.0000
0.999
Passed
Thermal Stress @ 80 °C 2 h
13.50
85.6
1.000
0.999
Passed
Photo Stress
Fluorescent 1.2 M Lux and UV-200 W h–1 (Sample in
ampule) direct exposure
1.29
100.9
1.000
0.999
Passed
Precision
Method Precision
Precision reflects
how closely measurements of the same homogeneous sample taken under
specified conditions agree across numerous measurements obtained from
multiple samplings. The six replicate prepared samples from the same
formulation batch were injected into HPLC, and the RSD% of 6 sample
analyte assays was calculated. The analyte assay RSD% was agreeable,
and the current method is precise. The chromatogram is shown in Figure .
Figure 3
Precision chromatogram:
6 individual sample preparations from a
homogeneous sample expressing the closeness of agreement between series
of measurements.
Precision chromatogram:
6 individual sample preparations from a
homogeneous sample expressing the closeness of agreement between series
of measurements.
Intermediate Precision (after 4 days)
Variations within laboratories can be expressed by intermediate
precision: different days, different analysts, or different equipment.
Six test samples were prepared and injected into diverse HPLC columns
on different days. In analytical procedures, precision is usually
measured as variance, standard deviation, or the coefficient of variation.
The RSD% of 6 samples of analyte assay was calculated and the results
found to be within the limit.The F value and F critical value for both the method precision and intermediate
precision and the USP monograph method and current method (Method
Precision data) were calculated, and we observed that the F value < F critical value. Similarly,
the T value and T critical value
for both the method precision and intermediate precision and the USP
monograph method and current method (Method Precision data) were calculated,
and we observed that the T value < F critical value (one tail and two tail). The statistical data reject
the null hypothesis and indicate that the two different sets of data
and the two different methods of data are not statistically significant. Table and Table show the T and F test data.
Table 4
Method Ruggedness Analysis Data (F
and T-test)
Results
(Recovery %)
Test
Parameter
Acceptance Criteria
EDTA
BA
CMN
Method Precision
n = 6 (6 determinations at 100% specification level)
Recovery at each level should be 98–102%
99.3
100.2
100.1
100.2
100.1
100.6
99.4
100.2
100.3
100.2
100.1
99.8
99.6
101.2
100.1
100.1
100.7
101.6
Mean
99.8
100.4
100.4
RSD
0.4
0.4
0.6
Intermediate precision
n = 6 (6 determinations at 100%
specification level)
Recovery at each level
should be 98–102%
100.9
100.9
99.8
100.2
99.6
100.8
100.9
100.1
98.9
99.6
98.7
100.1
98.9
100.8
101.1
100.6
99.6
100.3
Mean
100.2
100
100.2
RSD
0.8
0.8
0.8
F-Test
Degrees of freedom
5
5
5
F-Value
0.8595
0.2861
0.5871
P-Value
0.4361
0.0979
0.2865
F-Critical One tail
F < F criticala
5.0503
5.0503
5.0503
T-Test
Degrees of freedom
5
5
5
T-Value
–0.9363
1.5349
0.6459
P-Value One tail
0.196
0.0927
0.2734
T-Critical One tail
T < T criticala
2.015
2.015
2.015
P-Value Two tail
0.3921
0.1854
0.5468
T-Critical Two tail
T < T criticala
2.5706
2.5706
2.5706
Indicates reject null hypothesis,
i.e., no statistical significance (differences) observed between the
data performed on different days.
Table 5
Method Comparison Analysis Data with
USP Method (F and T-test)
Results (Recovery (%), Precision
(%RSD)
Test
Parameter
Acceptance Criteria
CMN
USP Method
n = 6 (6 determinations at 100% specification level)
Recovery at each level should be 98–102%
99.3
100.2
99.4
100.2
99.6
100.1
Mean
99.8
RSD
0.4
Current Method
n = 6 (6 determinations
at 100% specification level)
Recovery at
each level should be 98–102%
100.9
100.2
100.9
99.6
98.9
100.6
Mean
100.2
RSD
0.8
F-test
Degrees of freedom
5
F-Value
0.8595
P-Value
0.4361
F-Critical One tail
F < F criticala
5.0503
T-Test
Degrees of freedom
5
T-Value
–0.9363
P-Value One tail
0.196
T-Critical One tail
T < T criticala
2.015
P-Value Two tail
0.3921
T-Critical Two tail
T < T criticala
2.5706
Indicates reject null hypothesis,
i.e., no statistical significance (differences) observed between the
current and USP method.
Indicates reject null hypothesis,
i.e., no statistical significance (differences) observed between the
data performed on different days.Indicates reject null hypothesis,
i.e., no statistical significance (differences) observed between the
current and USP method.
Linearity
Analytical procedures
that are linear are those in which the response is directly proportional
to the analyte concentration present in the sample. The linearity
samples were prepared at 25%, 50%, 75%, 100%, 125%, and 150% levels
of target concertation of three analytes and injected in triplicate
to calculate the correlation coefficient value for three analytes.
The correlation coefficient value was >0.999, and the method obeys
the Beer–Lambert law. Hence the current process is linear.
The chromatogram is shown in Figure .
Figure 4
Linearity Chromatogram: EDTA linearity from 0.1 μg/mL
to
0.8 μg/mL, BA linearity from 2.4 μg/mL to 14.2 μg/mL,
and CMN linearity from 37.5 μg/mL to 225.0 μg/mL.
Linearity Chromatogram: EDTA linearity from 0.1 μg/mL
to
0.8 μg/mL, BA linearity from 2.4 μg/mL to 14.2 μg/mL,
and CMN linearity from 37.5 μg/mL to 225.0 μg/mL.
Accuracy
In analytical procedures,
trueness is how the value found accedes to the true conventional value
or accepted reference value. The trueness of the method was established
by preparing the LOQ (LOQ of the three analytes was determined by
injecting low concentrations and considering the ICH guideline S/N
ratio method and determined the LOQ), 80%, 100%, and 120% level samples.
For each level, four determinations of a total of nine samples are
prepared by spiking the analytes at LOQ, 80%, 100%, and 120% levels
into the placebo. The sample is injected into HPLC, with six replicates,
and recoveries are found between 98.0% and 102.0% at target concentations
of 99.3% to 100.5% for EDTA, 99.3% to 100.8% for BA, and 99.1% to
100.3% for CMN. The results prove the accuracy of the method.
Robustness
A method’s robustness
can be defined as its competency to preserve its performance while
undergoing minuscule but deliberate variations in method parameters
and can be habituated to determine its reliability. The current method’s
robustness was verified by using the QbD concept with Design Expert
software ver. 13. Critical quality attributes were identified as pH
of the buffer, flow rate (mL/min), organic ratio (mL), and column
compartment temperature (°C) changed to lower and higher levels
by the suggestion of ICH Q2 (R1)[26] and
USP general chapter ⟨621⟩.[28] Sample preparation, column, and wavelength variations did not affect
the proposed method and conditions. As evidenced by the method’s
precision and intermediate precision results, the instrument variation
did not impact the protocol. Four factorials with two levels, including
three center points without any blocks designed, were created, and
19 experimental runs were conducted, and results are tabulated in Table .
Table 6
DoE Trails HPLC Runs and Resultsa
Std
Run
F1
F2
F3
F4
R1
R2
R3
R4
R5
R6
R7
R8
R9
1
1
180
4.3
0.9
30
15.852
1.02
14985
9.885
1.01
18612
4.018
1.22
8691
9
2
180
4.3
0.9
40
15.431
1.11
14961
9.695
1.02
18672
3.990
1.29
8591
10
3
220
4.3
0.9
40
10.785
1.10
14895
7.861
1.10
18912
3.109
1.22
8599
14
4
220
4.3
1.2
40
10.236
1.10
14695
7.618
1.09
18961
3.011
1.22
8609
6
5
220
4.3
1.2
30
10.432
1.10
14985
7.625
1.06
18931
3.012
1.24
8589
5
6
180
4.3
1.2
30
15.631
1.02
14985
9.654
1.10
18329
3.889
1.26
8591
18
7
200
4.5
1.05
35
13.310
1.01
14795
8.691
1.06
18686
3.516
1.22
8561
4
8
220
4.7
0.9
30
10.985
1.11
14985
7.859
1.07
18628
3.210
1.22
8593
11
9
180
4.7
0.9
40
15.426
1.11
14785
9.881
1.08
18625
3.995
1.28
8596
2
10
220
4.3
0.9
30
10.980
1.11
14886
7.951
1.06
18966
3.215
1.26
8599
13
11
180
4.3
1.2
40
15.625
1.10
14986
9.610
1.09
18961
3.88
1.26
8641
7
12
180
4.7
1.2
30
15.618
1.10
14894
9.610
1.08
18967
3.900
1.26
8601
19
13
200
4.5
1.05
35
13.412
1.02
14785
8.701
1.08
18966
3.525
1.21
8618
15
14
180
4.7
1.2
40
15.628
1.11
14985
9.605
1.09
18967
3.885
1.22
8591
8
15
220
4.7
1.2
30
10.438
1.13
14965
7.618
1.09
18968
3.005
1.22
8569
3
16
180
4.7
0.9
30
15.859
1.11
14786
9.881
1.09
18933
4.020
1.20
8439
12
17
220
4.7
0.9
40
10.881
1.17
14889
7.856
1.07
18967
3.090
1.22
8597
16
18
220
4.7
1.2
40
10.231
1.11
14869
7.610
1.06
18639
3.010
1.22
8569
17
19
200
4.5
1.05
35
13.215
1.02
14815
8.598
1.07
18639
3.510
1.21
8598
F1: Organic_ACN mL, F2: pH, F3:
Flow rate mL min–1, and F4: Column temperature °C.
R1: CMN retention time (Rt), R2: CMN Tailing
factor (Tf), and R3: CMN Plate count (N). R4: BA retention time (Rt), R5: BA Tailing factor (Tf), and R6:
BA Plate count (N). R7: EDTA retention time (Rt), R8: EDTA Tailing factor (Tf), and R8: EDTA Plate count (N).
F1: Organic_ACN mL, F2: pH, F3:
Flow rate mL min–1, and F4: Column temperature °C.
R1: CMN retention time (Rt), R2: CMN Tailing
factor (Tf), and R3: CMN Plate count (N). R4: BA retention time (Rt), R5: BA Tailing factor (Tf), and R6:
BA Plate count (N). R7: EDTA retention time (Rt), R8: EDTA Tailing factor (Tf), and R8: EDTA Plate count (N).Three analytes’ retention time (R1, R4, and
R7), tailing
factor (R2, R5, and R8), and theoretical plates (R3, R6, and R9) were
monitored. For the statistical evaluation, the significant factors
were selected and analyzed. Results visualize the variations in retention
time and no impact on tailing and plate count are seen. Constructing
the results of the 3D plot was rolled into the Design Expert software
ver. 13. The ANOVA (analysis of variance) table (Table ) exhibited the design significance
and passed the model for R1, R4, and R7.
Table 7
ANOVA Table for Response Factors of
CMN, BA, and EDTA
R
Source
Sum of squares
df
Mean Square
F-value
p-value
R1
Model
16676.96
7
2382.42
6762.12
<0.0001
Significant
A-Organic
ACN
16551.60
1
16551.60
46979.06
<0.0001
C-Flow rate
42.49
1
42.49
120.61
<0.0001
D-Column temperature
25.35
1
25.35
71.96
<0.0001
AD
36.01
1
36.01
102.20
<0.0001
AC
1.48
1
1.48
4.20
0.0651
CD
8.47
1
8.47
24.04
0.0005
ACD
11.56
1
11.56
32.80
0.0001
Residual
3.88
11
0.3523
Lack of Fit
0.5985
9
0.0665
0.0406
0.9998
Not significant
Pure Error
3.28
2
1.64
Cor
total
16680.84
18
R4
Model
15.88
2
7.94
2206.94
<0.0001
Significant
A-Organic ACN
15.65
1
15.65
4349.40
<0.0001
C-Flow rate
0.2302
1
0.2302
63.98
<0.0001
Residual
0.0576
16
0.0036
Lack of Fit
0.0511
14
0.0037
1.13
0.5650
Not significant
Pure Error
0.0065
2
0.0032
Cor total
15.91
18
R7
Model
3.07
7
0.4389
11222.39
<0.0001
Significant
A-Organic
ACN
2.99
1
2.99
76408.12
<0.0001
C-Flow rate
0.0696
1
0.0696
1778.53
<0.0001
D-Column temperature
0.0056
1
0.0056
142.86
<0.0001
AD
0.0009
1
0.0009
21.87
0.0007
AC
0.0013
1
0.0013
33.60
0.0001
CD
0.0042
1
0.0042
107.19
<0.0001
ACD
0.0025
1
0.0025
64.56
<0.0001
Residual
0.0004
11
0.0000
Lack of Fit
0.0003
9
0.0000
0.6165
0.7497
Not significant
Pure Error
0.0001
2
0.0001
Cor total
3.07
18
Box-Cox diagnostics current lambda was equal to 1,
recommending
there be no data transformation. Organic ratio and flow rate changes
showed significant changes in the retention times of the three analytes,
but pH and column temperature changes are not impacting the chromatography.
Organic ratio and flow rate changes showed variations, but variations
met the system suitability criteria and concluded that the method
is robust. Figure shows the half-normal, 2D contour, and 3D surface plots.
Figure 5
(A) Half normal plot, Contour plot, and 3D plot of CMN
Retention
time. (B) Half normal plot, Contour plot, and 3D plot of BA Retention
time. (C) Half normal plot, Contour plot, and 3D plot of EDTA Retention
time.
(A) Half normal plot, Contour plot, and 3D plot of CMN
Retention
time. (B) Half normal plot, Contour plot, and 3D plot of BA Retention
time. (C) Half normal plot, Contour plot, and 3D plot of EDTA Retention
time.
Analytical Solution Stability
Establishment
of analytical solution stability is crucial for this method because
EDTA chromophore activation is the reason the derivatizing agent (Copper
II acetate) added to the solution. This study shows the derivatizing
agent’s impact on other analytes. To confirm the solution stability
under benchtop and refrigerator conditions, the prepared standard
and sample solutions were injected to HPLC at 0, 24, and 48 h as per
the method. The difference between the analyte assays in all time
points was <2.0%. At 0 h, the values were 1.3%, 0.5%, and 1.6%
for EDTA, BA, and CMN, respectively, on the benchtop, and 1.6%, 1.1%,
and 1.4% for EDTA, BA, and CMN, respectively, at 2–8 °C.
Standard and sample solutions were stable for 48 h on benchtop and
refrigerator conditions.
Method for Greenness Assessment
Green
chemistry is the design of chemical products and processes
that minimize or eliminate hazardous substances’ utilization
or generation. The greenness of the current method was assessed by
utilizing the analytical eco-score tool, calculating the penalty points.
The eco-score value of 80 is in the range of excellent greenness.
The penalty points table is tabulated in Table .
Table 8
Penalty Points Table for the Current
Method
Sample No
Reagents/Instruments
Penalty points
1
Acetate buffer
0
2
Acetonitrile
4
3
Copper acetate
1
4
Acetic acid
2
5
Tetra butyl ammonium hydroxide 10% in water
3
6
HPLC
1
7
Occupational hazard
0
8
waste
5
9
Total penalty points
16
10
Analytical Eco-Scale
84
Other tools like NEMI and an advanced tool, GAPI,
were used to
express the method greenness in the pictogram (Figure ). AGREE is a modern tool that evaluates
all 12 green principles using appropriate software. The AGREE circle
is divided into 12 parts; each part describes one green principle,
and the estimated AGREE value of the current method is 0.68 (Figure ). All four tools
signify the current method is green and eco-friendly.
Figure 6
NEMI, GAPI, and AGREE
pictograms of the current method. In NMEI,
GAPI and AGREE are marked green, yellow, or red depending on the impact
on the environment. Waste disposal was not discussed; hence waste
was not addressed in NEMI.
NEMI, GAPI, and AGREE
pictograms of the current method. In NMEI,
GAPI and AGREE are marked green, yellow, or red depending on the impact
on the environment. Waste disposal was not discussed; hence waste
was not addressed in NEMI.
Authors: P Pérez-Lozano; E García-Montoya; A Orriols; M Miñarro; J R Ticó; J M Suñé-Negre Journal: J Pharm Biomed Anal Date: 2005-07-20 Impact factor: 3.935